Spruce Biosciences Q3 net loss $12.4M; completes enrollment in two key CAH trials

SPRUCE BIOSCIENCES, INC.

2023-Q3 EPS reported -$1.01 revenue$7,202,000

Net loss $12.4M for Q3 2023 vs. $11.4M same period 2022; revenue $3.1M (Kaken collaboration).
Cash, equivalents, investments $108.0M; expected to fund operations into H1 2025.
Enrollment completed in CAHptain-205 (pediatric, 30 patients) and CAHmelia-203 (adult, >72 patients).
CAHmelia-204 enrollment >75% on track for early Q1 2024 completion.
Topline data expected Q1 2024 for CAHmelia-203 & CAHptain-205; Q3 2024 for CAHmelia-204.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SPRUCE BIOSCIENCES, INC. reported the third quarter ended September 30, 2023 results: net income $12.4 million.

Period: the third quarter ended September 30, 2023
Net income: $12.4 million
Result: reported results

Exact text from the filing

Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

View on SEC.gov

Browse all earnings releases →

SPRUCE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-062936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.